Episode 24: A Between the Biotech Waves conversation with John Hoffman, managing director & head of healthcare equity capital markets at Credit Suisse
Between the Biotech Waves
00:00
The Depressing Future of Biotech
The best thing about the new year is that it's not 2022. So I think we're all happy to be operating in 2023. The telling up here from me today around predictions for 23 is going to be a whole lot more optimistic than what they were during 2022. There was a lot of cross currents, both on the macro side and the biotech side specifically that just created a really, really tough operating environment.
Play episode from 01:33
Transcript
